Skip to main content

Advertisement

SpringerLink
Log in

RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Raf kinase inhibitor protein (RKIP) is an inhibitor of Raf-mediated activation of mitogen-activated protein (MAP) kinase (MEK)-MAP kinase and is considered as an important tumor suppressor. RKIP-expression was investigated retrospectively in 321 esophageal cancers [179 adenocarcinomas (ACs), 142 squamous cell carcinomas (SCCs)]. RKIP-expression was further investigated in 41 precursor lesions consisting of 14 cases of non-dysplastic Barrett’s mucosa, 5 low grade dysplasias (LGD), and 12 high grade dysplasias (HGD) as well as, 4 cases with low grade and 6 cases with high-grade squamous cell dysplasia. Corresponding lymph node metastases were investigated in 140 patients, distant metastases in 29, and local recurrences in 12. High RKIP-expression was significantly more common in Barrett’s mucosa without dysplasia and in LGD compared to HGD (p = 0.047, χ2 test) and invasive AC (p < 0.001, χ2 test). In 187 primary esophageal cancers (58.3 %) RKIP was downregulated (AC: 51.4 %; SCC: 66.9 %). RKIP status of primary tumors influenced RKIP expression in corresponding lymph node and distant metastases (p < 0.05, linear regression). Downregulation of RKIP was associated with shorter overall survival (OS) and disease free survival (DFS) in all tumors (p ≤ 0.05, Cox regression). In AC, downregulation of RKIP was an independent prognostic factor for OS and DFS (p ≤ 0.05, Cox regression), while in SCC it reached significance only in univariate analysis (p ≤ 0.05, log-rank test). In conclusion, downregulation of RKIP is associated with shorter survival in esophageal cancers, and RKIP status of tumor cells seems to be preserved at the formation of metastases. Inhibition of RKIP-downregulation might reduce the ability of esophageal cancers to establish disseminated disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jones PA, Takai D (2001) The role of DNA methylation in mammalian epigenetics. Science 293(5532):1068–1070

    Article  PubMed  CAS  Google Scholar 

  2. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16(1):6–21

    Article  PubMed  CAS  Google Scholar 

  3. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5(1):37–50

    Article  PubMed  CAS  Google Scholar 

  4. Yeung K et al (2000) Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 20(9):3079–3085

    Article  PubMed  CAS  Google Scholar 

  5. Yeung K et al (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401(6749):173–177

    Article  PubMed  CAS  Google Scholar 

  6. Al-Mulla F et al (2008) Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J Clin Pathol 61(4):524–529

    Article  PubMed  CAS  Google Scholar 

  7. Yeung KC et al (2001) Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 21(21):7207–7217

    Article  PubMed  CAS  Google Scholar 

  8. Ku GY, Ilson DH (2010) Esophagogastric cancer: targeted agents. Cancer Treat Rev 36(3):235–248

    Article  PubMed  CAS  Google Scholar 

  9. Driessen A et al (2006) Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 243(3):334–340

    Article  PubMed  Google Scholar 

  10. Tanaka N et al (2008) Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 99(9):1468–1475

    Article  PubMed  CAS  Google Scholar 

  11. Beshir AB et al (2010) Raf kinase inhibitor protein suppresses nuclear factor-kappaB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett 299(2):137–149

    Article  PubMed  CAS  Google Scholar 

  12. Li TT et al (2009) Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7(7):1064–1077

    Article  PubMed  CAS  Google Scholar 

  13. Li HZ et al (2009) Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res 7(6):832–840

    Article  PubMed  CAS  Google Scholar 

  14. Li HZ et al (2008) Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res 6(6):917–928

    Article  PubMed  CAS  Google Scholar 

  15. Schuierer MM et al (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64(15):5186–5192

    Article  PubMed  CAS  Google Scholar 

  16. Chatterjee D et al (2004) RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279(17):17515–17523

    Article  PubMed  CAS  Google Scholar 

  17. Woods Ignatoski KM et al (2008) Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys 72(1):153–160

    Article  PubMed  CAS  Google Scholar 

  18. Zaravinos A et al (2009) BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma. Cell Cycle 8(9):1402–1408

    Article  PubMed  CAS  Google Scholar 

  19. Paulson TG et al (2009) Chromosomal instability and copy number alterations in Barrett’s esophagus and esophageal adenocarcinoma. Clin Cancer Res 15(10):3305–3314

    Article  PubMed  CAS  Google Scholar 

  20. Ruan L et al (2010) Raf kinase inhibitor protein correlates with sensitivity of nasopharyngeal carcinoma to radiotherapy. J Cell Biochem 110(4):975–981

    Article  PubMed  CAS  Google Scholar 

  21. Zlobec I et al (2008) Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer 99(10):1712–1717

    Article  PubMed  CAS  Google Scholar 

  22. Minoo P et al (2007) Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 127(5):820–827

    Article  PubMed  Google Scholar 

  23. Hagan S et al (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 11(20):7392–7397

    Article  PubMed  CAS  Google Scholar 

  24. Fu Z et al (2006) Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66(3):248–256

    Article  PubMed  CAS  Google Scholar 

  25. Chatterjee D et al (2008) Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 14(10):2994–3001

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors indicate to have no financial disclosures, conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Institute of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Peter Birner

  2. Department of Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria

    Bettina Jesch & Sebastian F. Schoppmann

  3. Institute of Pathology, Kaiserin-Elisabeth Spital, Huglgasse 1-3, 1150, Vienna, Austria

    Andrea Schultheis

Authors
  1. Peter Birner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bettina Jesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Schultheis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sebastian F. Schoppmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sebastian F. Schoppmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Birner, P., Jesch, B., Schultheis, A. et al. RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases. Clin Exp Metastasis 29, 551–559 (2012). https://doi.org/10.1007/s10585-012-9470-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-012-9470-8

Keywords

Search

Navigation